BioSpace News Archive

Pictured: Human lung anatomy concept/iStock, magic

Business

New Biotech Targets Rare Respiratory Disorders with Inhaled Gene Therapies

AlveoGene has licensed the U.K. Respiratory Gene Therapy Consortium’s InGenuiTy platform for all uses excluding the CTFR gene, which is already licensed to Boehringer Ingelheim for cystic fibrosis.

September 14, 2023

·

2 min read

·

Kate Goodwin

Pictured: A vial of Fentanyl_nito100, iStock

As Impact of Substance Use Disorders Rise, So Do Innovative Solutions

From reversing overdose to blocking cravings, the biopharma industry is looking at a range of possible solutions to addiction.

September 14, 2023

·

4 min read

·

Hayley Shasteen

Virscio's St. Kitts Research Vivarium, Virscio

Drug Development

African Green Monkeys Play Key Role in Advancing Preclinical Research Amid Supply Chain Shortage

As researchers face delayed project timelines and inflated costs, industry leaders are offering an alternative option for sourcing nonhuman primates.

September 14, 2023

·

5 min read

·

BioSpace Insights

Pictured: AbbVie Corporate Office/iStock, vzphotos

Business

AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program

The company declined to exercise the license option for Harpoon Therapeutics’ TriTAC HPN217 program for multiple myeloma, which targets B cell maturation antigen, or BCMA.

September 14, 2023

·

2 min read

·

Tristan Manalac

Policy

6 Key Regulatory Guidance Documents Issued in 2023

The FDA has issued more than 30 guidance documents related to drug development so far this year. BioSpace takes a closer look at six of them.

September 14, 2023

·

5 min read

·

Heather McKenzie

Pictured: Bristol Myers Squibb in NJ/iStock, arlut

Drug Development

BMS Culls Two Mid-Stage, Four Early-Stage Clinical Programs

Bristol Myers Squibb’s pipeline cuts, announced Thursday during its R&D Day, include a mid-stage drug candidate for nonalcoholic steatohepatitis and an anti-TIGIT solid tumor program.

September 14, 2023

·

3 min read

·

Connor Lynch

Pictured: Facade of Moderna's building in Massachusetts

Drug Development

Moderna Axes Four Clinical Development Programs, Two AstraZeneca Had Dropped

During Wednesday’s annual R&D Day, Moderna said it is culling four programs from its pipeline, including two molecules that had been discontinued last year by AstraZeneca.

September 14, 2023

·

2 min read

·

Tristan Manalac

Pictured: Pile of money/iStock, Ihor Lukianenko

Generate Raises $273M in Series C Financing with New Investors Amgen, NVIDIA

In the largest biotech Series C financing so far this year, Generate:Biomedicines picked up new investors including Amgen and NVIDIA’s venture capital arm to advance its pipeline of 17 programs.

September 14, 2023

·

2 min read

·

Tristan Manalac

Deals

Neumora Therapeutics Announces Pricing of Initial Public Offering

Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of 14,710,000 shares of its common stock at a price to the public of $17.00 per share.

September 14, 2023

·

3 min read

Pharm Country

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium.

September 14, 2023

·

6 min read